(NYSE Amex Equities : CVM)

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.38%125.270.0%$2654.10m
BNGOBioNano Genomics, Inc. 11.74%9.420.0%$1883.27m
GILDGilead Sciences, Inc. 6.12%67.211.0%$665.19m
CRSPCRISPR Therapeutics AG -1.38%197.130.6%$575.00m
AMGNAmgen, Inc. 1.10%248.191.3%$558.30m
NVAXNovavax, Inc. 4.30%132.9192.9%$488.94m
REGNRegeneron Pharmaceuticals, Inc. 2.81%532.502.7%$470.49m
ALXNAlexion Pharmaceuticals, Inc. 1.42%158.932.0%$463.97m
ILMNIllumina, Inc. 2.57%386.013.5%$368.45m
SRPTSarepta Therapeutics, Inc. 6.59%96.2713.8%$339.45m
VRTXVertex Pharmaceuticals, Inc. 2.86%232.011.9%$337.08m
BIIBBiogen, Inc. 0.59%277.471.7%$336.96m
BNTXBioNTech SE 2.23%103.860.0%$321.49m
OCGNOcugen, Inc. 4.10%2.310.0%$317.86m
PACBPacific Biosciences of California, Inc. 7.52%39.707.4%$274.67m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.